organization · Reporting owner
TANG CAPITAL MANAGEMENT LLC
Disclosed activity across 12 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | 10% owner | May 29, 2026 | June 03, 2026 |
| Bio Green Med Solution, Inc.CYCC · Entity 8225 | 10% owner | February 23, 2017 | February 27, 2017 |
| Boundless Bio, Inc.BOLD · Entity 7063 | 10% owner | August 26, 2026 | August 28, 2026 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | 10% owner | July 16, 2026 | July 21, 2026 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | 10% owner | September 12, 2018 | September 12, 2018 |
| Jounce Therapeutics, Inc.JNCE · Entity 15754 | 10% owner | May 03, 2023 | May 05, 2023 |
| Odonate Therapeutics, Inc.ODT · Entity 132524 | 10% owner | November 17, 2021 | November 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date May 29, 2026 · Filed June 03, 2026
Jointly reported with TANG KEVIN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy LP | 13,044,106 |
Last balance in matching sequence
After 2026-06-02 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-05-29 · Purchase · Acquired 2,299 · Balance 12,231,799 F1: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.33 to $15.38. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 6. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Row 2 · 2026-05-29 · Purchase · Acquired 262,682 · Balance 12,494,481 F3: These shares were purchased in multiple transactions ranging from $15.05 to $15.37. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Row 3 · 2026-06-01 · Purchase · Acquired 343,521 · Balance 12,838,002 F4: These shares were purchased in multiple transactions ranging from $14.97 to $15.50. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Row 4 · 2026-06-01 · Purchase · Acquired 99 · Balance 12,838,101 F5: These shares were purchased at $15.34. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Row 5 · 2026-06-02 · Purchase · Acquired 206,005 · Balance 13,044,106 F6: These shares were purchased in multiple transactions ranging from $15.00 to $15.40. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). |
| Short Put Options (potential obligation to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2027-01-15 | IndirectBy LP | 10,000 |
Reported balance
After 2026-06-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-02 · Other · Acquired 10,000 · Balance 10,000 F7: Each put option is exercisable only at the option of the counterparty through the expiration date of the put option. F8: Securities are beneficially held by TCP III and TCP IV. The Funds sold 10,000 put options on June 2, 2026. Pursuant to the put option contracts, the Funds have the potential obligation to acquire 1,000,000 common shares of the Issuer at $15 expiring on January 15, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.33 to $15.38. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 6.
F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds").
F3: These shares were purchased in multiple transactions ranging from $15.05 to $15.37.
F4: These shares were purchased in multiple transactions ranging from $14.97 to $15.50.
F5: These shares were purchased at $15.34.
F6: These shares were purchased in multiple transactions ranging from $15.00 to $15.40.
F7: Each put option is exercisable only at the option of the counterparty through the expiration date of the put option.
F8: Securities are beneficially held by TCP III and TCP IV. The Funds sold 10,000 put options on June 2, 2026. Pursuant to the put option contracts, the Funds have the potential obligation to acquire 1,000,000 common shares of the Issuer at $15 expiring on January 15, 2027.
Bio Green Med Solution, Inc.
Report date February 23, 2017 · Filed February 27, 2017
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 559,900 |
Reported balance
After 2017-02-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-02-23 · Purchase · Acquired 134,200 · Balance 559,900 F1: This transaction was executed in multiple trades at prices ranging from $4.09 to $4.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $4.09 to $4.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.
Boundless Bio, Inc.
Report date August 26, 2026 · Filed August 28, 2026
Jointly reported with TANG KEVIN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,840,635 |
Reported balance
After 2026-08-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-26 · Sale · Disposed 18,300 · Balance 2,840,635 F1: The Reporting Persons have delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $10,046.70. F2: The price reported herein is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.03. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares sold at each price within the range set forth in Footnote 2. F3: Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 887,715 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 642,589 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Persons have delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $10,046.70.
F2: The price reported herein is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.03. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares sold at each price within the range set forth in Footnote 2.
F3: Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 887,715 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 642,589 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
Fulcrum Therapeutics, Inc.
Report date July 16, 2026 · Filed July 21, 2026
Jointly reported with TANG KEVIN
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,080,945 |
Last balance in matching sequence
After 2026-07-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-16 · Purchase · Acquired 116,671 · Balance 7,030,000 F1: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3. F2: Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Row 2 · 2026-07-17 · Purchase · Acquired 50,945 · Balance 7,080,945 F3: These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.55. F2: Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3.
F2: Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
F3: These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.55.
HERON THERAPEUTICS, INC. /DE/
Report date September 12, 2018 · Filed September 12, 2018
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 5,830,215 |
Reported balance
After 2018-09-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-09-12 · Sale · Disposed 2,695,000 · Balance 5,830,215 F1: The Reporting Person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 192,308 shares of common stock purchased by the Reporting Person on March 29, 2018. The Reporting Person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein. F2: The securities are held by Tang Capital Partners, LP. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP. |
| Common StockSEC Table I · non-derivative | IndirectAs Trustee | 14,347 |
Reported balance
Holding disclosure · report date 2018-09-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,347 F3: The securities are held by Kevin C. Tang as custodian for his minor children, as Trustee of the Kevin C. Tang Family Trust, and as Trustee of the Tang Advisors, LLC Profit Sharing Plan. |
| Common StockSEC Table I · non-derivative | Direct | 6,941 |
Reported balance
Holding disclosure · report date 2018-09-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,941 F4: 2,147 of these securities are held by Kevin C. Tang's IRA. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 192,308 shares of common stock purchased by the Reporting Person on March 29, 2018. The Reporting Person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein.
F2: The securities are held by Tang Capital Partners, LP. Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP.
F3: The securities are held by Kevin C. Tang as custodian for his minor children, as Trustee of the Kevin C. Tang Family Trust, and as Trustee of the Tang Advisors, LLC Profit Sharing Plan.
F4: 2,147 of these securities are held by Kevin C. Tang's IRA.
Jounce Therapeutics, Inc.
Report date May 03, 2023 · Filed May 05, 2023
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2023-05-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-05-03 · Other · Disposed 5,300,087 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 26, 2023, by and among the Issuer, Concentra Biosciences, LLC, ("Concentra"), and Concentra Merger Sub, Inc., a wholly-owned subsidiary of Concentra ("Merger Sub"), to which Concentra completed a tender offer (the "Offer") for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.85 per Share (the "Cash Consideration") plus one non-transferable contractual contingent value right per Share (each, a "CVR," and each CVR together with the Cash Consideration, the "Offer Price"). From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $73,118.01. F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
| Common StockSEC Table I · non-derivative | IndirectBy LP | 10,000 |
Reported balance
After 2023-05-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-05-03 · Other · Acquired 10,000 · Balance 10,000 F4: On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs. F5: The shares are beneficially owned by Concentra. Concentra is wholly owned by TCP. Kevin Tang is the sole manager of TCM, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by Concentra. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 26, 2023, by and among the Issuer, Concentra Biosciences, LLC, ("Concentra"), and Concentra Merger Sub, Inc., a wholly-owned subsidiary of Concentra ("Merger Sub"), to which Concentra completed a tender offer (the "Offer") for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.85 per Share (the "Cash Consideration") plus one non-transferable contractual contingent value right per Share (each, a "CVR," and each CVR together with the Cash Consideration, the "Offer Price"). From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $73,118.01.
F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
F4: On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs.
F5: The shares are beneficially owned by Concentra. Concentra is wholly owned by TCP. Kevin Tang is the sole manager of TCM, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by Concentra.
Odonate Therapeutics, Inc.
Report date November 17, 2021 · Filed November 19, 2021
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP, Hearne Michael S
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 12,767,435 |
Last balance in matching sequence
After 2021-11-19 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
8 source rowsRow 1 · 2021-11-17 · Sale · Disposed 468,849 · Balance 15,045,717 F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 2 · 2021-11-17 · Sale · Disposed 31,151 · Balance 15,014,566 F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 3 · 2021-11-17 · Sale · Disposed 500,000 · Balance 14,514,566 F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 4 · 2021-11-17 · Sale · Disposed 287,577 · Balance 14,226,989 F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 5 · 2021-11-18 · Sale · Disposed 212,423 · Balance 14,014,566 F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 6 · 2021-11-18 · Sale · Disposed 500,000 · Balance 13,514,566 F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 7 · 2021-11-18 · Sale · Disposed 381,842 · Balance 13,132,724 F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 8 · 2021-11-19 · Sale · Disposed 365,289 · Balance 12,767,435 F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein.
F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005.
F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07.
F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33.
F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16.
F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99.
F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001.
F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aptevo Therapeutics Inc.
Report date November 23, 2021 · Filed November 26, 2021
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP
Section 16 reporting ended · disclosed 2021-11-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Last balance in matching sequence
After 2021-11-23 transaction · row 7
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rowsRow 1 · 2021-11-23 · Sale · Disposed 161,336 · Balance 760,000 F1: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 8 herein. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 2 · 2021-11-23 · Sale · Disposed 124,509 · Balance 635,491 F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.97 to $12.90. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 3 · 2021-11-23 · Sale · Disposed 75,491 · Balance 560,000 F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.59 to $11.89. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 4 · 2021-11-23 · Sale · Disposed 149,111 · Balance 410,889 F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.67. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 5 · 2021-11-23 · Sale · Disposed 50,889 · Balance 360,000 F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.31 to $10.64. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 6 · 2021-11-23 · Sale · Disposed 200,000 · Balance 160,000 F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.59 to $10.34. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 7 · 2021-11-23 · Sale · Disposed 160,000 · Balance 0 F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.20. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 8 herein.
F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP.
F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.97 to $12.90.
F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.59 to $11.89.
F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.67.
F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.31 to $10.64.
F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.59 to $10.34.
F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.20.
LA JOLLA PHARMACEUTICAL CO
Report date August 22, 2022 · Filed August 24, 2022
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP, Hearne Michael S
Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2022-08-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-08-22 · Other · Disposed 9,607,934 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. |
| Series C-1(2) Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy LP | 0 |
Reported balance
After 2022-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-22 · Other · Disposed 3,519.315 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP.
F3: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price.
Rain Oncology Inc.
Report date January 26, 2024 · Filed February 02, 2024
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP
Section 16 reporting ended · disclosed 2024-02-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2024-01-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-01-26 · Other · Disposed 3,850,513 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 13, 2023, by and among the Issuer, Pathos AI, Inc. ("Parent"), and WK Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, to which Parent completed a tender offer for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.16 per Share plus one contingent value right for potential cash payments of up to approximately $0.17 per Share. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $18,729.24. F3: The Reporting Persons received the following in exchange for each Share tendered in connection with the Merger: $1.16 in cash per Share and one contingent value right for potential cash payments of up to approximately $0.17 per Share. F4: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 13, 2023, by and among the Issuer, Pathos AI, Inc. ("Parent"), and WK Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, to which Parent completed a tender offer for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.16 per Share plus one contingent value right for potential cash payments of up to approximately $0.17 per Share. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $18,729.24.
F3: The Reporting Persons received the following in exchange for each Share tendered in connection with the Merger: $1.16 in cash per Share and one contingent value right for potential cash payments of up to approximately $0.17 per Share.
F4: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
Singular Genomics Systems, Inc.
Report date February 21, 2025 · Filed February 28, 2025
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP
Section 16 reporting ended · disclosed 2025-02-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2025-02-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-02-21 · Disposition to issuer · Disposed 372,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 22, 2024, by and among Singular Genomics Systems, Inc. (the "Issuer"), Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 22, 2024, by and among Singular Genomics Systems, Inc. (the "Issuer"), Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings.
F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
TCR2 THERAPEUTICS INC.
Report date June 01, 2023 · Filed February 14, 2024
Jointly reported with TANG KEVIN, TANG CAPITAL PARTNERS LP
Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2023-06-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-06-01 · Other · Disposed 4,394,800 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics, Inc. (the "Issuer"), Adaptimmune Therapeutics plc ("Parent"), and CM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Issuer, Parent, and Merger Sub, to which Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 1.5117 American Depository Shares of Parent ("Parent ADS"), representing six ordinary shares of Parent. F2: The Reporting Persons received 1.5117 Parent ADSs in exchange for each Share cancelled in connection with the Merger. F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics, Inc. (the "Issuer"), Adaptimmune Therapeutics plc ("Parent"), and CM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Issuer, Parent, and Merger Sub, to which Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 1.5117 American Depository Shares of Parent ("Parent ADS"), representing six ordinary shares of Parent.
F2: The Reporting Persons received 1.5117 Parent ADSs in exchange for each Share cancelled in connection with the Merger.
F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2023 Filed Feb 14, 2024 22:25 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | OtherCommon Stock | 4,394,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-003784 · form4-02142024_100232.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics, Inc. (the "Issuer"), Adaptimmune Therapeutics plc ("Parent"), and CM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Issuer, Parent, and Merger Sub, to which Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 1.5117 American Depository Shares of Parent ("Parent ADS"), representing six ordinary shares of Parent. F2 · price: The Reporting Persons received 1.5117 Parent ADSs in exchange for each Share cancelled in connection with the Merger. F3 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 22:46 UTC | Rain Oncology Inc. RAIN · Entity 94695 | PurchaseCommon Stock | 5,000 | $1.10 | $5,500.00 |
DisclosureSEC source: 0001209191-23-033446 · doc4.xml · nonDerivative · entry 7 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 3,407,016 F8 · price: These shares were purchased in one transaction at $1.10. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 22:46 UTC | Rain Oncology Inc. RAIN · Entity 94695 | PurchaseCommon Stock | 161,180 | $1.08 | $174,074.40 |
DisclosureSEC source: 0001209191-23-033446 · doc4.xml · nonDerivative · entry 6 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 3,402,016 F7 · price: These shares were purchased in multiple transactions ranging from $1.04 to $1.10. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 22:46 UTC | Rain Oncology Inc. RAIN · Entity 94695 | PurchaseCommon Stock | 5,930 | $1.06 | $6,285.80 |
DisclosureSEC source: 0001209191-23-033446 · doc4.xml · nonDerivative · entry 5 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 3,240,836 F6 · price: These shares were purchased in multiple transactions ranging from $1.02 to $1.08. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 22:46 UTC | Rain Oncology Inc. RAIN · Entity 94695 | PurchaseCommon Stock | 2,016 | $1.08 | $2,177.28 |
DisclosureSEC source: 0001209191-23-033446 · doc4.xml · nonDerivative · entry 4 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 3,234,906 F5 · price: These shares were purchased in multiple transactions ranging from $1.075 to $1.08. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 22:46 UTC | Rain Oncology Inc. RAIN · Entity 94695 | PurchaseCommon Stock | 32,890 | $1.06 | $34,863.40 |
DisclosureSEC source: 0001209191-23-033446 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 3,232,890 F4 · price: These shares were purchased in multiple transactions ranging from $1.05 to $1.08. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 22:46 UTC | Rain Oncology Inc. RAIN · Entity 94695 | PurchaseCommon Stock | 200,000 | $1.00 | $200,000.00 |
DisclosureSEC source: 0001209191-23-033446 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 3,200,000 F3 · price: These shares were purchased in multiple transactions ranging from $0.96 to $1.03. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 22:46 UTC | Rain Oncology Inc. RAIN · Entity 94695 | PurchaseCommon Stock | 347,932 | $1.05 | $365,328.60 |
DisclosureSEC source: 0001209191-23-033446 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 3,000,000 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $0.96 to $1.15. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1, and Footnotes 3 through 10 herein. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 25, 2023 Filed May 31, 2023 00:02 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 50,000 | $1.72 | $86,000.00 |
DisclosureSEC source: 0001209191-23-033041 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 4,394,800 F1 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1 herein. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 12, 2023 Filed May 15, 2023 21:12 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 6,183 | $1.95 | $12,056.85 |
DisclosureSEC source: 0001209191-23-029527 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 4,344,800 F3 · price: These shares were purchased in multiple transactions at $1.95. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:12 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 38,765 | $1.95 | $75,591.75 |
DisclosureSEC source: 0001209191-23-029527 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 4,338,617 F1 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $1.93 to $1.95. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 herein. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 10, 2023 Filed May 10, 2023 23:02 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 6,774 | $1.95 | $13,209.30 |
DisclosureSEC source: 0001209191-23-028565 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 4,299,852 F4 · price: These shares were purchased in multiple transactions at prices ranging from $1.945 to $1.95. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 09, 2023 Filed May 10, 2023 23:02 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 20,141 | $1.95 | $39,274.95 |
DisclosureSEC source: 0001209191-23-028565 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 4,293,078 F3 · price: These shares were purchased in multiple transactions at prices ranging from $1.92 to $1.95. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 08, 2023 Filed May 10, 2023 23:02 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 57,073 | $1.95 | $111,292.35 |
DisclosureSEC source: 0001209191-23-028565 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 4,272,937 F1 · price: The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $1.94 to $1.95. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4 herein. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 05, 2023 Filed May 5, 2023 22:52 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 71,064 | $1.94 | $137,864.16 |
DisclosureSEC source: 0001209191-23-027833 · doc4.xml · nonDerivative · entry 4 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 4,215,864 F5 · price: The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.93 to $1.95. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 05, 2023 Filed May 5, 2023 22:52 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 95,759 | $1.90 | $181,942.10 |
DisclosureSEC source: 0001209191-23-027833 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 4,144,800 F4 · price: The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.88 to $1.94. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:52 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 104,241 | $1.86 | $193,888.26 |
DisclosureSEC source: 0001209191-23-027833 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 4,049,041 F3 · price: The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.90. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 03, 2023 Filed May 5, 2023 22:52 UTC | TCR2 THERAPEUTICS INC. TCRR · Entity 94327 | PurchaseCommon Stock | 18,513 | $1.85 | $34,249.05 |
DisclosureSEC source: 0001209191-23-027833 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 3,944,800 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $1.84 to $1.85. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3, 4 and 5 herein. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:37 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | OtherCommon Stock | 10,000 | $9,737.70 | $97,377,000.00 |
DisclosureSEC source: 0001209191-23-027688 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 10,000 F4 · kind: On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs. F4 · price: On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs. F5 · ownership.nature: The shares are beneficially owned by Concentra. Concentra is wholly owned by TCP. Kevin Tang is the sole manager of TCM, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by Concentra. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:37 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | OtherCommon Stock | 5,300,087 | $1.85 | $9,805,160.95 |
DisclosureSEC source: 0001209191-23-027688 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 26, 2023, by and among the Issuer, Concentra Biosciences, LLC, ("Concentra"), and Concentra Merger Sub, Inc., a wholly-owned subsidiary of Concentra ("Merger Sub"), to which Concentra completed a tender offer (the "Offer") for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.85 per Share (the "Cash Consideration") plus one non-transferable contractual contingent value right per Share (each, a "CVR," and each CVR together with the Cash Consideration, the "Offer Price"). From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2 · kind: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $73,118.01. F3 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 00:39 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | PurchaseCommon Stock | 20,286 | $1.02 | $20,651.15 |
DisclosureSEC source: 0001209191-23-018721 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 5,300,087 F3 · price: The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.02. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 00:39 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | PurchaseCommon Stock | 65,701 | $0.99 | $65,306.79 |
DisclosureSEC source: 0001209191-23-018721 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 5,279,801 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 herein. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | OtherSeries C-1(2) Convertible Preferred Stock · Derivative | 3,519.315 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-047314 · doc4.xml · derivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 0 Underlying: Common Stock · 6,067,439 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-1(2) Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | OtherCommon Stock | 9,607,934 | $6.23 | $59,857,428.82 |
DisclosureSEC source: 0001209191-22-047314 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| December 01, 2021 Filed Dec 1, 2021 19:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | SaleCommon Stock | 41,290 | $3.66 | $151,303.08 |
DisclosureSEC source: 0001209191-21-067347 · doc4.xml · nonDerivative · entry 5 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,607,934 F7 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.60 to $3.75 F3 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. F3 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| December 01, 2021 Filed Dec 1, 2021 19:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | SaleCommon Stock | 136,255 | $3.76 | $512,128.04 |
DisclosureSEC source: 0001209191-21-067347 · doc4.xml · nonDerivative · entry 4 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,649,224 F6 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.89. F3 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. F3 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 19:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | SaleCommon Stock | 63,745 | $3.95 | $251,544.14 |
DisclosureSEC source: 0001209191-21-067347 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,785,479 F5 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.051. F3 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. F3 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 19:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | SaleCommon Stock | 6,597 | $3.95 | $26,067.39 |
DisclosureSEC source: 0001209191-21-067347 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,849,224 F4 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.95 to $3.96. F3 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. F3 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 19:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | SaleCommon Stock | 193,403 | $4.10 | $793,107.02 |
DisclosureSEC source: 0001209191-21-067347 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Director · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 9,855,821 F1 · kind: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $4,380.25. F2 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $3.90 to $4.74. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 and 4 through 7 herein. F3 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. F3 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in the shares beneficially held by TCP. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 18:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 160,000 | $9.60 | $1,536,560.00 |
DisclosureSEC source: 0001209191-21-066910 · doc4.xml · nonDerivative · entry 7 TANG KEVIN C · CIK 0001178579 · Exit Filing TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · Exit Filing TANG CAPITAL PARTNERS LP · CIK 0001191935 · Exit Filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 0 F8 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.20. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 18:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 200,000 | $10.07 | $2,014,440.00 |
DisclosureSEC source: 0001209191-21-066910 · doc4.xml · nonDerivative · entry 6 TANG KEVIN C · CIK 0001178579 · Exit Filing TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · Exit Filing TANG CAPITAL PARTNERS LP · CIK 0001191935 · Exit Filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 160,000 F7 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.59 to $10.34. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 18:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 50,889 | $10.43 | $530,665.40 |
DisclosureSEC source: 0001209191-21-066910 · doc4.xml · nonDerivative · entry 5 TANG KEVIN C · CIK 0001178579 · Exit Filing TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · Exit Filing TANG CAPITAL PARTNERS LP · CIK 0001191935 · Exit Filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 360,000 F6 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.31 to $10.64. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 18:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 149,111 | $11.19 | $1,668,432.80 |
DisclosureSEC source: 0001209191-21-066910 · doc4.xml · nonDerivative · entry 4 TANG KEVIN C · CIK 0001178579 · Exit Filing TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · Exit Filing TANG CAPITAL PARTNERS LP · CIK 0001191935 · Exit Filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 410,889 F5 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.67. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 18:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 75,491 | $11.74 | $886,430.42 |
DisclosureSEC source: 0001209191-21-066910 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · Exit Filing TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · Exit Filing TANG CAPITAL PARTNERS LP · CIK 0001191935 · Exit Filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 560,000 F4 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.59 to $11.89. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 18:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 124,509 | $12.45 | $1,550,186.85 |
DisclosureSEC source: 0001209191-21-066910 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · Exit Filing TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · Exit Filing TANG CAPITAL PARTNERS LP · CIK 0001191935 · Exit Filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 635,491 F3 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.97 to $12.90. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 18:02 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 161,336 | $13.52 | $2,181,520.86 |
DisclosureSEC source: 0001209191-21-066910 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · Exit Filing TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · Exit Filing TANG CAPITAL PARTNERS LP · CIK 0001191935 · Exit Filing Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 760,000 F1 · price: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 8 herein. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 22, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 38,664 | $6.55 | $253,372.92 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 10 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 921,336 F11 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.71. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 22, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 3,719 | $6.66 | $24,778.58 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 9 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 960,000 F10 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $6.66 to $6.68. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 22, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 196,281 | $7.11 | $1,395,184.98 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 8 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 963,719 F9 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $6.69 to $7.69. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 22, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 16,667 | $7.36 | $122,650.79 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 7 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 1,160,000 F8 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $7.20 to $7.54. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 21:38 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | SaleCommon Stock | 365,289 | $1.92 | $699,930.25 |
DisclosureSEC source: 0001209191-21-065826 · doc4.xml · nonDerivative · entry 8 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 12,767,435 F9 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 183,333 | $7.52 | $1,378,755.83 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 6 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 1,176,667 F7 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $7.20 to $8.09. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 30,467 | $8.01 | $244,110.74 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 5 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 1,360,000 F6 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $7.78 to $8.15. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:38 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | SaleCommon Stock | 381,842 | $1.89 | $722,635.99 |
DisclosureSEC source: 0001209191-21-065826 · doc4.xml · nonDerivative · entry 7 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 13,132,724 F8 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:38 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | SaleCommon Stock | 500,000 | $1.88 | $940,600.00 |
DisclosureSEC source: 0001209191-21-065826 · doc4.xml · nonDerivative · entry 6 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 13,514,566 F7 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 21:38 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | SaleCommon Stock | 212,423 | $1.97 | $418,643.25 |
DisclosureSEC source: 0001209191-21-065826 · doc4.xml · nonDerivative · entry 5 TANG KEVIN C · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Hearne Michael S · CIK 0001759910 · Chief Financial Officer Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 14,014,566 F6 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16. F2 · ownership.direct: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 169,533 | $8.09 | $1,372,318.78 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 4 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 1,390,467 F5 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.34. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 4,023 | $8.00 | $32,190.03 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 3 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 1,560,000 F4 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.01. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 152,764 | $8.32 | $1,271,515.88 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 2 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 1,564,023 F3 · price: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $8.04 to $9.04. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 22:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | SaleCommon Stock | 43,213 | $9.38 | $405,532.40 |
DisclosureSEC source: 0001209191-21-066146 · doc4.xml · nonDerivative · entry 1 TANG KEVIN C · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner TANG CAPITAL PARTNERS LP · CIK 0001191935 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LP Disclosed balance after: 1,716,787 F1 · price: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $9.05 to $10.05. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 11 herein. F2 · ownership.direct: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. F2 · ownership.nature: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.